Senti Biosciences Inc (SNTI)
$2.15
+0.04
(+1.9%)▲
Performance
- $2.13$2.21$2.15
1.16%
Downside
Day's Volatility :3.85%
Upside
2.72%
- $1.52$8.48$2.15
29.3%
Downside
52 Weeks Volatility :82.07%
Upside
74.64%
Returns
| Period | Senti Biosciences Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -32.81% | 3.8% | 0.0% |
6 Months | -36.48% | 10.8% | 0.0% |
1 Year | -32.39% | 18.9% | 0.0% |
3 Years | -78.26% | 22.8% | -20.8% |
Highlights
Market Capitalization | 9.7M |
Book Value | $9.65 |
Earnings Per Share (EPS) | -17.54 |
Wall Street Target Price | 6.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -18017.46% |
Return On Assets TTM | -33.02% |
Return On Equity TTM | -111.07% |
Revenue TTM | 338.0K |
Revenue Per Share TTM | 0.08 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | -29.8M |
EBITDA | -56.6M |
Diluted Eps TTM | -17.54 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 179.07%
Technicals Summary
Sell
Neutral
Buy
Senti Biosciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Senti Biosciences Inc | -30.65% | -36.48% | -32.39% | -78.26% | -78.37% |
 Regeneron Pharmaceuticals, Inc. | -12.78% | 12.27% | 21.13% | 86.55% | 232.53% |
 Novo Nordisk A/s | -12.16% | -3.59% | 19.82% | 145.88% | 361.43% |
 Alnylam Pharmaceuticals, Inc. | 8.63% | 91.46% | 72.01% | 39.76% | 259.26% |
 Vertex Pharmaceuticals Incorporated | 0.64% | 21.48% | 30.9% | 167.3% | 177.5% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Senti Biosciences Inc | NA | NA | NA | 0.0 | -1.11 | -0.33 | NA | 9.65 |
Regeneron Pharmaceuticals, Inc. | 26.88 | 26.88 | 1.38 | 45.01 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.83 | 40.83 | 1.8 | 3.37 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.38 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.58 | 0.33 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Senti Biosciences Inc | Buy | $9.7M | -78.37% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.1B | 232.53% | 26.88 | 32.04% |
Novo Nordisk A/s | Buy | $523.9B | 361.43% | 40.83 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $36.5B | 259.26% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $124.3B | 177.5% | 32.84 | -4.74% |
Insights on Senti Biosciences Inc
Increasing Revenue
Revenue is up for the last 3 quarters, 255.0K → 333.0K (in $), with an average increase of 11.7% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -18.71M → -11.20M (in $), with an average increase of 31.3% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 72.0% return, outperforming this stock by 104.4%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 39.8% return, outperforming this stock by 118.1%
Institutional Holdings
NEA Management Company, LLC
9.67%ARK Investment Management LLC
3.56%Vanguard Group Inc
1.54%Intel Corp
1.30%Hongkou Capital LP
0.68%Geode Capital Management, LLC
0.54%
Company Information
senti biosciences is a team of engineers, scientists, and entrepreneurs on a mission to leverage synthetic biology to treat the most pressing diseases. they have pioneered new technology platforms to design synthetic gene circuits for adaptive cell and gene therapies. their recently completed series a round of funding will be used to further the growth of their scalable therapeutic design platform and advance therapeutic candidates towards the clinic. they are proud to count nea, 8vc, amgen ventures, pear ventures, lux capital, menlo ventures, allen & company, nest.bio, omega funds, goodman capital, and lifeforce capital among their investors.
Organization | Senti Biosciences Inc |
Employees | 48 |
CEO | Dr. Timothy K. Lu M.D., Ph.D. |
Industry | Financial |
